DEX Immunotherapy and Surgery: Synergy That Redefines Modern Cancer Treatment

Authors

  • Ramon Gutierrez-Sandoval Department of Oncopathology, OGRD Alliance, Lewes, De, USA Author
  • Ider Rivadeneira Department of Outreach and Engagement Programs for OGRD Consortium, Charlestown, KN0802, Saint Kitts and Nevis, USA Author
  • Adolay Sobarzo Department of Biological and Chemistry Sciences, Faculty of Medicine and Science, San Sebastian University, Concepción, Chile Author
  • Ignacio Muñoz Department of Outreach and Engagement Programs for OGRD Consortium, Charlestown, KN0802, Saint Kitts and Nevis, USA Author
  • Jordan Iturra Department of Outreach and Engagement Programs for OGRD Consortium, Charlestown, KN0802, Saint Kitts and Nevis, USA Author
  • Francisco Krakowiak Department of Molecular Oncopathology, Bioclas, Concepcion, Chile Author
  • Rodrigo Aguilera Department of Molecular Oncopathology, Bioclas, Concepcion, Chile Author
  • Cristian Peña Vargas Department of Outreach and Engagement Programs for OGRD Consortium, Charlestown, KN0802, Saint Kitts and Nevis, USA Author

DOI:

https://doi.org/10.47363/JMHC/2024(6)290

Keywords:

Chimeric Antigen Receptors, Circulating Tumor Cells, Cytotoxic T-Lymphocyte Antigen, Dendritic Cell-Derived Exosomes

Abstract

Cancer represents one of the most complex medical challenges of our time. Over the decades, standard approaches have included the combination of surgery, chemotherapy, and radiotherapy. While effective in many cases, these strategies have significant limitations, particularly when time becomes a critical factor [1]. One of the most controversial areas in modern oncology is the decision to delay surgery in certain cancers, such as colon, breast, and other solid tumors, in favor of prolonged neoadjuvant chemotherapy [2]. This strategy, designed to reduce tumor size and target micrometastases, can, in some cases, weaken the patient and postpone surgical intervention, which might otherwise have had a significant impact on early reduction of total tumor burden.

Author Biographies

  • Ramon Gutierrez-Sandoval, Department of Oncopathology, OGRD Alliance, Lewes, De, USA

    Department of Oncopathology, OGRD Alliance, Lewes, De, USA

  • Ider Rivadeneira, Department of Outreach and Engagement Programs for OGRD Consortium, Charlestown, KN0802, Saint Kitts and Nevis, USA

    Department of Outreach and Engagement Programs for OGRD Consortium, Charlestown, KN0802, Saint Kitts and Nevis, USA

  • Adolay Sobarzo, Department of Biological and Chemistry Sciences, Faculty of Medicine and Science, San Sebastian University, Concepción, Chile

    Department of Biological and Chemistry Sciences, Faculty of Medicine and Science, San Sebastian University, Concepción, Chile

  • Ignacio Muñoz, Department of Outreach and Engagement Programs for OGRD Consortium, Charlestown, KN0802, Saint Kitts and Nevis, USA

    Department of Outreach and Engagement Programs for OGRD Consortium, Charlestown, KN0802, Saint Kitts and Nevis, USA

  • Jordan Iturra, Department of Outreach and Engagement Programs for OGRD Consortium, Charlestown, KN0802, Saint Kitts and Nevis, USA


    Department of Outreach and Engagement Programs for OGRD Consortium, Charlestown, KN0802, Saint Kitts and Nevis, USA

  • Francisco Krakowiak, Department of Molecular Oncopathology, Bioclas, Concepcion, Chile

    Department of Molecular Oncopathology, Bioclas, Concepcion, Chile

  • Rodrigo Aguilera, Department of Molecular Oncopathology, Bioclas, Concepcion, Chile

    Department of Molecular Oncopathology, Bioclas, Concepcion, Chile 

  • Cristian Peña Vargas, Department of Outreach and Engagement Programs for OGRD Consortium, Charlestown, KN0802, Saint Kitts and Nevis, USA

    Department of Outreach and Engagement Programs for OGRD Consortium, Charlestown, KN0802, Saint Kitts and Nevis, USA

Downloads

Published

2024-12-26